Elicera Therapeutics
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue
On 20 February 2024 the extraordinary general meeting of the Company resolved on a rights issue of units of approximately SEK 64 million (the “Rights Issue”). The subscription period in the Rights Issue started on 23 February 2024 and ends 8 March 2024. Elicera has received additional subscription commitments from the following members of the board and management who intend to subscribe in the Rights Issue:
| Shareholder | Role in the Company | Initial commitment, SEK | Increased commitment, SEK |
| Jamal El-Mosleh | CEO | 250,000 | 100,000 |
| Di Yu | Head of Translational Research and co-fonder | 100,000 | 100,000 |
| Jan Zetterberg | Board member | 0 | 230,000 |
| Total | 350,000 | 430,000 |
Through these subscription commitments, the board and management demonstrate their continued confidence in Elicera’s future prospects. Overall the subscription commitments from the board and management amount to approximately 1 million SEK.
| Datum | 2024-03-04, kl 14:00 |
| Källa | Cision |
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet